12:00 AM
 | 
Feb 08, 2016
 |  BC Week In Review  |  Company News  |  Deals

Abzena deal

Abzena granted an undisclosed U.S. cancer company non-exclusive rights to use Abzena’s ThioBridge antibody drug conjugate (ADC)...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >